Cytotoxic chemotherapy has not been effective for advanced disease and clinical trials testing imatinib to target KIT over-expression [45] or lapatinib for HER activation [46] have been unsuccessful for ACC; Although activation of FGFR has been proposed as another candidate target for ACC that is currently under clinical investigation; more work is needed to define the core cancer signaling pathways and to identify new cancer treatment targets. This evidence concerns the gene KIT and adrenal cortex carcinoma.